{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:40:41Z","timestamp":1767847241291,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010460","name":"U.S. Army Medical Command","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010460","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.annonc.2020.03.309","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T19:25:33Z","timestamp":1586633133000},"page":"930-941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"S.","family":"Halabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Tangen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.P.","family":"Petrylak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"I.M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.S.","family":"De Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Eisenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.I.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.S.","family":"Higano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.F.","family":"Tannock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.J.","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.K.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.03.309_bib1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/pros.20052","article-title":"Explaining racial differences in prostate cancer in the United States: sociology or biology?","volume":"62","author":"Freedland","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.annonc.2020.03.309_bib2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pros.10055","article-title":"Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men","volume":"50","author":"Eastham","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.annonc.2020.03.309_bib3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2105\/AJPH.94.5.803","article-title":"Racial differences in survival among men with prostate cancer and comorbidity at time of diagnosis","volume":"94","author":"Freeman","year":"2004","journal-title":"Am J Public Health"},{"key":"10.1016\/j.annonc.2020.03.309_bib4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/pros.21314","article-title":"Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer","volume":"71","author":"Chornokur","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.annonc.2020.03.309_bib5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jnci\/93.5.388","article-title":"Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study","volume":"93","author":"Hoffman","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2020.03.309_bib6","first-page":"193","article-title":"The epidemiology of prostate cancer part II: the risk factors","volume":"16","author":"Brawley","year":"1998","journal-title":"Semin Urol Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib7","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1200\/JCO.2013.50.7723","article-title":"Re-examining racial disparities in prostate cancer outcomes","volume":"20","author":"Cooperberg","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/jnci\/93.3.219","article-title":"Association of African-American ethnic background with survival in men with metastatic prostate cancer","volume":"93","author":"Thompson","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2020.03.309_bib9","first-page":"1164","article-title":"Improved overall survival trends of men with newly diagnosed m1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)","volume":"188","author":"Tangen","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.annonc.2020.03.309_bib10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.urology.2004.04.014","article-title":"Impact of race on survival in men with metastatic hormone refractory prostate cancer","volume":"64","author":"Halabi","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.annonc.2020.03.309_bib11","first-page":"81","article-title":"Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of eight Cancer and Leukemia Group B (CALGB) studies","volume":"176","author":"Halabi","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.annonc.2020.03.309_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.18.01279","article-title":"Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel","volume":"37","author":"Halabi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib13","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"A\u00a0meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib14","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.309_bib15","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.03.309_bib16","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2010.32.8815","article-title":"Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer","volume":"29","author":"Scher","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib17","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401","volume":"30","author":"Kelly","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib18","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2012.46.4149","article-title":"Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer","volume":"31","author":"Fizazi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1470-2045(13)70294-8","article-title":"Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial","volume":"14","author":"Quinn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib20","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","article-title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial","volume":"14","author":"Tannock","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib21","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(13)70479-0","article-title":"Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial","volume":"14","author":"Araujo","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1470-2045(15)70025-2","article-title":"Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"16","author":"Petrylak","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1470-2045(17)30168-7","article-title":"Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial","volume":"18","author":"Chi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib24","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2)","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2020.03.309_bib25","doi-asserted-by":"crossref","first-page":"pkaa003","DOI":"10.1093\/jncics\/pkaa003","article-title":"Comparative survival of asian and white metastatic castration-resistant prostate cancer men treated with docetaxel","volume":"4","author":"Halabi","year":"2020","journal-title":"JNCI Cancer Spectrum"},{"key":"10.1016\/j.annonc.2020.03.309_bib26","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of black race with prostate cancer-specific and other-cause mortality","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib27","doi-asserted-by":"crossref","first-page":"69709","DOI":"10.18632\/oncotarget.19068","article-title":"Ethnic heterogeneity and prostate cancer mortality in Hispanic\/Latino men: a population-based study","volume":"8","author":"Chinea","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2020.03.309_bib28","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/1055-9965.EPI-09-0329","article-title":"Cancer incidence in first generation U.S. Hispanics: Cubans, Mexicans, Puerto Ricans, and new Latinos","volume":"18","author":"Pinheiro","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.annonc.2020.03.309_bib29","first-page":"425","article-title":"Cancer statistics for Hispanics\/Latinos, 2018","volume":"68","author":"Miller","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2020.03.309_bib30","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/annonc\/mdx041","article-title":"Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States","volume":"28","author":"Mahal","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.03.309_bib31","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.28617","article-title":"Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period","volume":"120","author":"Aizer","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.03.309_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"Role of clinical trial participation in cancer research: barriers, evidence, and strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.annonc.2020.03.309_bib33","doi-asserted-by":"crossref","first-page":"a030387","DOI":"10.1101\/cshperspect.a030387","article-title":"Prostate cancer disparities by race and ethnicity: from nucleotide to neighborhood","volume":"8","author":"Rebbeck","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.annonc.2020.03.309_bib34","first-page":"85","article-title":"The individualization of cancer therapy: the unexpected role of p53","volume":"117","author":"Hait","year":"2016","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.annonc.2020.03.309_bib35","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.1073\/pnas.1600420113","article-title":"Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression","volume":"113","author":"Komura","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annonc.2020.03.309_bib36","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/bjc.2016.251","article-title":"Loss of SLCO1B3 drives taxane resistance in prostate cancer","volume":"115","author":"de Morr\u00e9e","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2020.03.309_bib37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/1535-7163.MCT-11-0289","article-title":"Identification of docetaxel resistance genes in castration-resistant prostate cancer","volume":"11","author":"Mar\u00edn-Aguilera","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2020.03.309_bib38","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/pros.21496","article-title":"Suggestive evidence of linkage identified at chromosomes 12q24 and 2p16 in African American prostate cancer families from Louisiana","volume":"72","author":"Ledet","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.annonc.2020.03.309_bib39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.urology.2016.07.045","article-title":"Racial\/ethnic disparity in treatment for prostate cancer: does cancer severity matter?","volume":"99","author":"Moses","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.annonc.2020.03.309_bib40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.18865\/ed.27.3.201","article-title":"Racial differences in prostate cancer treatment: the role of socioeconomic status","volume":"27","author":"Watson","year":"2017","journal-title":"Ethn Dis"},{"issue":"9","key":"10.1016\/j.annonc.2020.03.309_bib41","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2105\/AJPH.2006.102525","article-title":"Approaching health disparities from a population perspective: the National Institutes of Health Centers for Population Health and Health Disparities","volume":"98","author":"Warnecke","year":"2008","journal-title":"Am J Public Health"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420364140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420364140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:58:04Z","timestamp":1760335084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420364140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0923753420364140"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.03.309","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.03.309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}